COVID-19 Nasal Swab Test Market, by Product Type (Foam Tipped Swabs, Non-Woven, and Others), by Diagnostics Type (Molecular Diagnostics, CRISPR & Biosensors, and Others), by Mode (Point-of-Care and Non Point-of-Care), by End User (Hospital & Clinic, Labor

COVID-19 Nasal Swab Test Market, by Product Type (Foam Tipped Swabs, Non-Woven, and Others), by Diagnostics Type (Molecular Diagnostics, CRISPR & Biosensors, and Others), by Mode (Point-of-Care and Non Point-of-Care), by End User (Hospital & Clinic, Laboratories & Diagnostics Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

COVID-19 infection is caused by SARS-CoV-2, which is a highly transmissible and life-threatening strain of coronavirus. Nasal swab is a method used for collecting clinical test samples of nasal secretions. Nasal swabs can be used for analysis of number of infectious diseases such as whooping cough, influenza, SARS, COVID-19, and others. Rising burden of COVID-19 cases across the world has created a huge opportunity for growth of COVID-19 nasal swab market. These nasal swabs can be used in laboratories as well as in the comfort of one’s home. The collection procedure must be carried out with extreme precautions as any contamination of the nasal swab may lead to wrong results. The collected nasal secretion sample is placed into a transporting medium that provides a stable environment to the sample. This transporting liquid medium is subjected to further diagnostic tests to detect the presence of SARS-CoV-2 in the nasal specimen.

Market Dynamics

Market players and private healthcare organizations are focused on conducting research activities for developing more efficient nasal swabs for detection of COVID-19 infection, which could contribute to the growth of the COVID-19 nasal swab test market over the forecast period. For instance, in March 2021, PATH, Mayo Clinic and Bill and Melinda Gates Foundation initiated an observational clinical study to compare the efficiency of foam nasal swabs and polyester nasal swabs in diagnosis of COVID-19 infection. This study was completed in October 2021, and it also focused on observing the trajectory of COVID-19 at different stages of infection.

Market players are focused on launch of products, which is expected to strengthen their position in the global COVID-19 nasal swab test market. For instance, in November 2021, Tata Medical and Diagnostics launched its product TataMD CHECK, a nasal swab test that is able to diagnose COVID-19 within 90 minutes.

Market players are involved in expanding their presence globally by entering into partnership with other companies in order to enhance distribution, this is expected to drive the growth of the COVID-19 nasal swab test market. For instance, in January 2021, iMFLUX, Inc., an American molding company entered into a partnership with Rhinostics, Inc., a Harvard University startup, to develop polypropylene COVID-19 nasal swab, which is cost effective and allows easy collection of nasal secretion.

Key features of the study:
This report provides an in-depth analysis of global COVID-19 nasal swab test market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global COVID-19 nasal swab test market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories, Roche Holding AG, Becton Dickinson & Company, 3M Corporation, BioMerieux SA, Lucira Health, Mesa Biotech, Inc.,Siemens Healthineers AG, QIAGEN N.V., Cepheid, LumiraDx Ltd., Fluidigm Corporation, Quidel Corporation, GenMark Diagnostics, Inc., Sherlock Biosciences, PrivaPath Diagnostics Limited, and OraSure Technologies, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global COVID-19 nasal swab test market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the COVID-19 nasal swab test market
Detailed Segmentation:
Global COVID-19 Nasal Swab Test Market, By Product Type:
Foam Tipped Swabs
Non-Woven
Others
Global COVID-19 Nasal Swab Test Market, By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
Global COVID-19 Nasal Swab Test Market, By Mode:
Point-of-Care
Non Point-of-Care
Global COVID-19 Nasal Swab Test Market, By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
Global COVID-19 Nasal Swab Test Market, By Region:
North America
By Product Type:
Foam Tipped Swabs
Non-Woven
Others
By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
By Mode:
Point-of-Care
Non Point-of-Care
By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
By Country:
U.S.
Canada
Latin America
By Product Type:
Foam Tipped Swabs
Non-Woven
Others
By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
By Mode:
Point-of-Care
Non Point-of-Care
By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Foam Tipped Swabs
Non-Woven
Others
By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
By Mode:
Point-of-Care
Non Point-of-Care
By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product Type:
Foam Tipped Swabs
Non-Woven
Others
By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
By Mode:
Point-of-Care
Non Point-of-Care
By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East
By Product Type:
Foam Tipped Swabs
Non-Woven
Others
By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
By Mode:
Point-of-Care
Non Point-of-Care
By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Foam Tipped Swabs
Non-Woven
Others
By Diagnostics Type:
Molecular Diagnostics
CRISPR & Biosensors
Others
By Mode:
Point-of-Care
Non Point-of-Care
By End User:
Hospital & Clinic
Laboratories & Diagnostics Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Abbott Laboratories*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Roche Holding AG
Becton Dickinson & Company
3M Corporation
BioMerieux SA
Lucira Health
Mesa Biotech, Inc.
Siemens Healthineers AG
QIAGEN N.V.
Cepheid
LumiraDx Ltd.
Fluidigm Corporation
Quidel Corporation
GenMark Diagnostics, Inc.
Sherlock Biosciences
PrivaPath Diagnostics Limited
OraSure Technologies, Inc.
“*” marked represents similar segmentation in other categories in the respective section.